Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Results 1 - 20 of 355 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar littleoldmedng (< 20) Submitted: 11/21/2014 10:54:52 AM : Outperform Start Price: $100.64 GILD Score: +0.15

Good Value and bound to rebound. Time to get in

Recs

0
Member Avatar cmrk3 (28.38) Submitted: 11/19/2014 10:14:13 AM : Outperform Start Price: $39.82 GILD Score: +115.36

Saving lives through selling expensive medicine.

Recs

0
Member Avatar bdescent (69.55) Submitted: 11/18/2014 2:00:34 PM : Outperform Start Price: $102.79 GILD Score: -2.90

Nice pipeline.

Recs

0
Member Avatar TMFTiptree (25.73) Submitted: 11/14/2014 2:14:41 PM : Outperform Start Price: $101.60 GILD Score: -2.30

Innovative company with a strong pipeline of drugs, plus a blockbuster gaining momentum.

Recs

0
Member Avatar purplehayes4 (47.73) Submitted: 11/8/2014 7:09:24 AM : Outperform Start Price: $109.07 GILD Score: -9.35

R&D seems to be their strong suit. Will be a leader for many years to come.

Recs

0
Member Avatar jdbow (53.32) Submitted: 11/7/2014 10:47:20 AM : Outperform Start Price: $98.43 GILD Score: -7.29

needed a drug company in my portfolio and this look like a good one

Recs

0
Member Avatar natureperfect7 (< 20) Submitted: 10/31/2014 1:19:17 AM : Outperform Start Price: $109.91 GILD Score: -10.99

The produce is much needed and is successful.

Recs

0
Member Avatar JeffRossMD (< 20) Submitted: 10/30/2014 12:44:05 PM : Outperform Start Price: $113.70 GILD Score: -15.39

The biotech space is just heating up as new technologies are revolutionizing cancer and chronic disease processes.

Recs

0
Member Avatar bartlettmi (69.98) Submitted: 10/29/2014 12:57:20 PM : Outperform Start Price: $109.65 GILD Score: -12.56

Not just a Hep-C company... This stock's run is not over.

Recs

0
Member Avatar lernout1973 (38.19) Submitted: 10/29/2014 6:01:29 AM : Outperform Start Price: $109.85 GILD Score: -12.48

strong growth, generates massive cash, good chance/risk ratio

Recs

0
Member Avatar Deepvaluestocks (< 20) Submitted: 10/27/2014 4:40:05 PM : Outperform Start Price: $113.25 GILD Score: -16.14

GILD had the best in class treatment for Hepatitis C in Harvoni and trades at a forward PE under 13, which is very low considering the potential growth.

Recs

0
Member Avatar russfischer1013 (94.57) Submitted: 10/26/2014 11:58:13 PM : Outperform Start Price: $110.77 GILD Score: -14.74

valuation = $180

Recs

0
Member Avatar dplan4money (70.30) Submitted: 10/21/2014 9:58:40 PM : Outperform Start Price: $106.51 GILD Score: -11.82

HepC drug = money

Recs

0
Member Avatar philpanda (37.55) Submitted: 10/21/2014 11:43:25 AM : Outperform Start Price: $104.51 GILD Score: -10.73

Hiv/aids isnt going anywhere soon. I believe this company will continue to create life extending medication. truvada is a very important drug to the community. as more people become aware of it , the stock will see a gain.

Recs

0
Member Avatar gunngun (< 20) Submitted: 10/21/2014 6:02:05 AM : Underperform Start Price: $104.05 GILD Score: +11.10

It's gone up too much too fast and is due for a sizable correction.

Recs

0
Member Avatar Tophinater (28.86) Submitted: 10/20/2014 3:32:42 PM : Outperform Start Price: $102.07 GILD Score: -10.13

><)));'>

Recs

0
Member Avatar roger55 (< 20) Submitted: 10/19/2014 3:25:46 AM : Outperform Start Price: $101.15 GILD Score: -10.36

have new drug approved by fda

Recs

0
Member Avatar Sceaj (< 20) Submitted: 10/13/2014 10:15:07 AM : Outperform Start Price: $101.92 GILD Score: -10.27

Hep "C" drug - approved for Medicaid patients. That's huge.

Recs

0
Member Avatar PLocklar (23.80) Submitted: 10/12/2014 5:19:45 PM : Outperform Start Price: $104.49 GILD Score: -12.20

outperform

Recs

0
Member Avatar SegaRob (53.96) Submitted: 10/3/2014 1:03:42 PM : Outperform Start Price: $106.79 GILD Score: -10.89

Gilead's Hep C treatment is "top dog" and "first mover." Sofosbuvir (sovaldi) is a big hit and the new combo pill with Ledipasvir will be first all-oral and first interferon-free regimen for HCV. Moreover, it shows efficacy in all HCV genotypes. This is a huge potential! Also they have a successful portfolio of other drugs and track record making new drugs that will spur furtue growth. I am expecting EPS $8-10 in next year or so. Even with the big run this year, using a forward P/E ratio of 20, I think there's a good chance the stock could double in a few years or less from current prices under $107.

Featured Broker Partners


Advertisement